Skip to main content
News Icon

News categories: Publication

Possible SARS-CoV-2 mass testing with new technology

Prof. Dr. Jonathan Schmid-Burgk heads the new working group for "Functional Immunogenomics" at the Institute for Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn. As part of the newly established professorship and management position, the 34-year-old genome researcher is investigating the complex interplay between genes and our immune system. With the help of robotics and artificial intelligence (AI), he is developing new techniques for protein analysis in living human cells with programmable gene scissors. The aim is to accelerate the modification of the human genome in order to analyze it. Prof. Schmid-Burgk is currently working on a mass test for COVID-19 using the LAMP-Seq process he developed. He brings his new techniques to the Cluster of Excellence ImmunoSensation at the University of Bonn. Following his doctorate, for which he received the doctoral award from the Bonn University Society in 2017, his previous academic career led Prof. Schmid-Burgk to Cambridge (USA). There he spent three and a half years researching at the Broad Institute of MIT and Harvard - funded by a grant from the European Molecular Biology Organization (EMBO).

Related news

Dr. Clivia Lisowski und Prof. Christian Kurts

News categories: Publication

Immune cells in the liver help pigeons navigate

How do pigeons find their way home safely over distances of many kilometers? A research team from the University Hospital Bonn (UKB), the University of Bonn, the University of Duisburg-Essen, and the Max Planck Institute for Behavioral Biology has now discovered a previously unknown mechanism: specific immune cells in the liver may help the birds detect the Earth’s magnetic field. The findings have now been published in the journal Science.
View entry
News Icon

News categories: Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry
Wissenschaftler

News categories: Publication

Driver of inflammation after mild head injury

Mild traumatic brain injuries can lead to persistent memory problems and an increased risk of dementia. Yet, effective therapies to counteract these long-term consequences are still lacking. Dr. Dr. Sergio Castro-Gomez, Early Career Research Group Leader at the Institute of Physiology II of the University Hospital Bonn has discovered together with colleagues that the ASC protein. The research team hopes to identify new targets for future therapeutic strategies. The study, published in the Journal of Clinical Investigation, lays the foundation for upcoming clinical trials.
View entry

Back to the news overview